Table 3 The univariate cox regression analysis in cervical cancer patients
From: Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer
Factors | Disease-free survival | Overall survival | ||
|---|---|---|---|---|
HR (95%CI) | P value | HR (95%CI) | P value | |
The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells (n = 197) | ||||
 Age, years (≤ 44/ > 44) | 0.937 (0.405–2.169) | 0.879 | 1.281 (0.581–2.825) | 0.539 |
 Clinical stage (I/II–IV) | 3.511 (1.472–8.373) | 0.005 | 3.820 (1.702–8.573) | 0.001 |
 Tumor (T) status (1/2–4) | 0.128 (0.017–0.955) | 0.051 | 0.106 (0.014–0.783) | 0.058 |
 Nodal (N) status (0/1) | 2.798 (1.095–7.152) | 0.032 | 2.225 (0.893–5.542) | 0.086 |
 METTL3 in tumor cells (low/high) | 4.244 (1.730–10.413) | 0.002 | 5.502 (2.312–13.092) | 0.001 |
 METTL3 in tumor-infiltrating immune cells (low/high) | 4.857 (1.643–14.353) | 0.004 | 6.021 (2.074–17.474) | 0.001 |
 Number of CD33+ MDSCs (low/high) | 6.579 (1.946–22.241) | 0.002 | 5.755 (1.982–16.705) | 0.001 |
 Combination of METTL3 levels and CD33+MDSCs (low/ middle/ high) | 4.672(2.149–10.156) |  < 0.001 | 4.890(2.369–10.093) |  < 0.001 |
The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells in stage I (n = 127) | ||||
 Age, years (≤ 44/ > 44) | 0.364 (0.074–1.807) | 0.217 | 0.562 (0.140–2.250) | 0.416 |
 Tumor (T) status (1/2–4) | 0.033 (0.00–35.599) | 0.338 | 0.032 (0.000–22.782) | 0.305 |
 Nodal (N) status (0/1) | 2.736 (0.552–13.569) | 0.218 | 2.325 (0.483–11.20) | 0.293 |
 METTL3 in tumor cells (low/high) | 1.696 (0.424–6.783) | 0.455 | 2.184 (0.586–8.132) | 0.244 |
 METTL3 in tumor-infiltrating immune cells (low/high) | 6.489 (0.799–52.832) | 0.080 | 7.452 (0.932–59.588) | 0.058 |
 Number of CD33+ MDSCs (low/high) | 1.732 (0.414–7.250) | 0.452 | 2.085 (0.521–8.339) | 0.299 |
 Combination of METTL3 levels and CD33+MDSCs (low/ middle/ high) | 2.639 (0.896–7.775) | 0.078 | 3.071(1.056–8.931) | 0.039 |
The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells in stage II–IV (n = 70) | ||||
 Age, years (≤ 44/ > 44) | 0.953 (0.299–3.039) | 0.935 | 1.240 (0.404–3.804) | 0.707 |
 Tumor (T) status (1/2–4) | 0.145 (0.019–1.110) | 0.063 | 0.116 (0.015–0.874) | 0.537 |
 Nodal (N) status (0/1) | 2.554 (0.800–8.152) | 0.113 | 1.192 (0.623–5.869) | 0.257 |
 METTL3 in tumor cells (low/high) | 9.713 (2.697–34.978) | 0.001 | 13.199 (3.776–46.130) |  < 0.001 |
 METTL3 in tumor-infiltrating immune cells (low/high) | 5.373 (1.498–19.276) | 0.010 | 7.209 (2.070–25.106) | 0.002 |
 Number of CD33+ MDSCs (low/high) | 66.197 (0.891–4917.536) | 0.056 | 16.621 (2.199–125.660) | 0.006 |
 *Combination of METTL3 levels and CD33+MDSCs (low/ middle/ high) | 7.673 (2.420–24.324) | 0.001 | 7.286(2.667–19.902) |  < 0.001 |